arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
Published 2 years ago • 1K plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
0:51
os sensitivity analysis of darolutamide, docetaxel and adt in arasens
-
1:19
role of the addition of docetaxel to adt in mhspc
-
1:53
arasens: tolerability pharmacokinetic analyses of combo therapy with daro, adt and doc in mhspc
-
1:14
arasens: dialuramide plus adt and docetaxel in mhspc stratified by disease risk volume
-
0:54
the addition of darolutamide to adt reduces risk of metastasis in nonmetastatic crpc
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:02:01
max draper from alphagenix: trt side-effects men must understand
-
1:42
darolutamide and survival in mhspc: a plain language summary of the arasens study
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
3:28
updates on adt as monotherapy for management of mhspc
-
2:32
arasens: will combining different treatments improve prostate cancer survival?
-
1:41
the role of triplet therapy in men with metastatic castration sensitive prostate cancer
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
1:41
future developments in the treatment of prostate cancer
-
55:35
is there still a role for docetaxel in mhspc?
-
35:26
esou online: eau22 highlights in prostate cancer
-
3:27
chaarted: adt docetaxel for prostate cancer
-
1:03
dr. azad on the benefit of adding enzalutamide to adt in mhspc